10-Q: Akebia Therapeutics Swings to Profit on Vafseo Launch

Akebia Therapeutics reported a significant financial turnaround, achieving net income and substantial revenue growth driven by the successful U.S. launch of Vafseo, despite Auryxia's loss of exclusivity.

Summary

• Total revenues for the six months ended June 30, 2025, increased by 57% to $119.8 million, up from $76.3 million in the same period last year.
• Product revenue, net, surged by 61% to $116.3 million, primarily due to Vafseo's U.S. market entry in January 2025, contributing $25.3 million.
• Auryxia sales also increased by 26% to $90.9 million, despite losing exclusivity in March 2025.
• The company achieved a net income of $6.4 million for the six months ended June 30, 2025, a significant improvement from a net loss of $26.6 million in the prior year period.
• Cash and cash equivalents significantly increased to $137.3 million as of June 30, 2025, from $51.9 million at December 31, 2024.
• The accumulated deficit decreased to $1.672 billion as of June 30, 2025, from $1.678 billion at December 31, 2024, resulting in a shift to positive stockholders' equity of $29.2 million.
• Cost of goods sold decreased by 39% due to the full amortization of the Auryxia intangible asset as of December 31, 2024, which previously incurred $18.0 million in amortization expense.
• Research and development expenses increased by 19% to $20.8 million, driven by Vafseo clinical trial activities and other pipeline programs.
• The company completed a public offering in March 2025, raising net proceeds of $46.5 million, and an additional $1.6 million from the underwriters' option exercise in April 2025.
• An additional $10.0 million tranche of the BlackRock Credit Agreement was funded in February 2025, bringing the total facility to $55.0 million.
• The company is pursuing label expansion for Vafseo for non-dialysis dependent CKD patients, with a goal to initiate the VALOR Phase 3 cardiovascular outcome study by the end of 2025.

Sentiment

Score: 7

Explanation: The company demonstrated a strong financial turnaround with significant revenue growth and a shift to net income, largely driven by the successful Vafseo launch. Cash position improved substantially, and the accumulated deficit was reduced. However, ongoing risks related to Auryxia's loss of exclusivity, increased debt-related expenses, a material weakness in internal controls, and the inherent uncertainties of clinical development and regulatory challenges temper the overall positive sentiment.

Positives

• Achieved net income of $6.4 million for the six months ended June 30, 2025, a substantial improvement from a net loss of $26.6 million in the prior year.
• Total revenues increased by 57% to $119.8 million, driven by strong product sales.
• Vafseo's successful U.S. market entry in January 2025, securing commercial supply agreements covering nearly 100% of U.S. dialysis patients, contributed $25.3 million in product revenue.
• Auryxia product revenue increased by 26% to $90.9 million, demonstrating resilience despite the loss of exclusivity in March 2025, partly due to the authorized generic launch.
• Cash and cash equivalents significantly increased to $137.3 million, enhancing liquidity.
• The accumulated deficit was reduced, and stockholders' equity turned positive, indicating improved financial health.
• The intangible asset related to Auryxia was fully amortized, eliminating $18.0 million in amortization expense from cost of goods sold.
• Successful capital raises through a public offering ($48.1 million net) and an at-the-market facility ($18.4 million net) demonstrate access to funding.
• Vafseo received marketing authorization in Europe from the European Commission in June 2025, expanding its international commercial reach.

Negatives

• Auryxia lost exclusivity in the U.S. in March 2025, which is expected to negatively impact future revenue, despite the authorized generic.
• Interest expense significantly increased to $14.6 million for the six months ended June 30, 2025, primarily due to non-cash interest related to the Vifor settlement royalty liability.
• The change in fair value of warrant liability resulted in a $6.8 million expense for the six months ended June 30, 2025, reflecting an increase in the liability.
• The company identified a material weakness in internal control over financial reporting as of December 31, 2024, related to inventory accounting, which is still being remediated.
• The post-approval pediatric study for Auryxia's Hyperphosphatemia Indication is delayed, with the final report due in April 2024 not yet submitted.
• The company continues to incur significant R&D expenses, which increased by 19% to $20.8 million, and expects these to continue to be substantial.
• The company faces ongoing legal proceedings, including patent oppositions and a lawsuit challenging CMS's ESRD PPS inclusion of oral-only phosphate lowering therapies, which could impact Auryxia revenue.

Risks

• Incurred significant losses since inception and cannot guarantee future profitability, despite recent net income.
• May require substantial additional financing, and failure to obtain it on acceptable terms could force delays or termination of product development or commercialization efforts.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to products on unfavorable terms.
• Business is substantially dependent on the commercial success of Auryxia and Vafseo, and inability to maintain contracts with dialysis organizations could materially harm financial condition.
• Substantial competition, including generic versions of Auryxia and other therapies for CKD, may result in others commercializing products more successfully.
• International operations for Vafseo and ferric citrate subject the company to risks like political instability, changes in reimbursement policies, trade protection measures, and foreign currency fluctuations.
• Clinical drug development is lengthy and expensive with uncertain outcomes, potentially leading to delays or inability to complete development of product candidates or label expansion for Vafseo.
• Auryxia, Vafseo, or other product candidates may cause undesirable side effects or have other properties that delay or prevent marketing approval or limit commercial potential.
• May not obtain marketing approval for Vafseo label expansion (e.g., NDD-CKD) or other product candidates, or may experience significant delays.
• Failure to obtain or maintain adequate coverage, pricing, and reimbursement for Auryxia, Vafseo, or future approved products could materially adversely affect sales.
• Subject to complex regulatory schemes, and failure to comply with applicable laws could result in costly investigations, fines, penalties, or sanctions.
• Significant liability if determined to be promoting off-label use of products or violating the federal Anti-Kickback Statute.
• Disruptions at the FDA and other government agencies (e.g., funding cuts, personnel losses, regulatory reform) could hinder timely guidance and approval of product candidates.
• Legislative and regulatory healthcare reform (e.g., IRA, state pricing laws) may increase difficulty and cost of obtaining marketing approval and affect product prices.
• Dependence on collaborations with third parties (e.g., MTPC, Medice, AG Partner) for development and commercialization, and their failure or termination could harm the business.
• Reliance on third parties for product manufacturing and commercial distribution, with single suppliers in many instances, poses risks of supply chain disruptions or quality issues.
• Intellectual property rights may be limited, challenged, or fail to provide competitive advantage, especially with generic competition and ongoing patent oppositions.
• Security breaches and unauthorized use of information technology systems could damage clinical trials, impact regulatory filings, compromise intellectual property, and lead to regulatory actions.
• Employees, contractors, and vendors may engage in misconduct or improper activities, including non-compliance with regulatory standards or insider trading.
• Long-lived assets, including goodwill, could become impaired, significantly impacting results of operations and financial condition.
• Risk of product liability lawsuits, which could result in substantial liabilities and require limiting commercialization.
• Stock price volatility and potential delisting from Nasdaq could result in substantial losses for stockholders.
• Issuance or sale of additional common stock will dilute existing stockholders' ownership interest and may cause the market price to decline.

Future Outlook

The company believes its existing cash resources and expected revenues are sufficient to fund its current operating plan for at least twelve months, including commercializing Vafseo and Auryxia, pursuing Vafseo label expansion, and advancing other programs. It aims to initiate the VALOR Phase 3 cardiovascular outcome study for Vafseo in non-dialysis dependent CKD patients by the end of 2025. The company may seek additional financing through equity, debt, or strategic transactions if needed. Future Auryxia revenues are uncertain due to generic competition, though the ESRD bundle dynamics may slow decline. Vafseo's cost of product and other revenue is expected to increase after the utilization of reduced-cost inventory. The company anticipates incurring significant R&D expenses for ongoing and planned studies.

Management Comments

• We have built a business focused on developing and commercializing innovative therapeutics that we believe serves as a foundation for future growth.
• Our team has significant expertise in hypoxia-inducible factor, or HIF, science having developed and commercialized Vafseo (vadadustat) and have selected two additional HIF-based molecules for preclinical development.
• We have established the company as a leader in the kidney community, and we believe our cross-organizational expertise in renal disease positions the company for success.
• We are committed to pursuing a path for label expansion for Vafseo for CKD non-dialysis dependent patients.
• We believe the dynamics of Auryxia reimbursement being included in the ESRD bundle could result in a slower revenue decline after the LoE date than in other LoE situations.
• We believe our existing cash resources and the cash we expect to generate from product, royalty, supply and license revenues are sufficient to fund our current operating plan for the foreseeable future.

Industry Context

The company operates in the highly competitive biopharmaceutical industry, specifically targeting complications of kidney disease, including anemia and hyperphosphatemia. The U.S. CKD market is substantial, affecting approximately 37 million patients. Vafseo is positioned as the only oral HIF-based treatment for anemia due to CKD in U.S. dialysis patients, a market estimated at $1 billion. Auryxia competes in the phosphate binder market, which has seen reduced growth since early 2020, partly due to the COVID-19 pandemic's disproportionate impact on CKD patients and labor shortages affecting dialysis providers. The inclusion of oral-only phosphate binders and Vafseo in the ESRD bundle as of January 2025 is a significant reimbursement change, with transitional add-on payments (TDAPA) for Vafseo for at least two years. The industry faces increasing scrutiny over drug pricing, with federal and state legislative efforts and ongoing litigation (e.g., Ardelyx vs. CMS) potentially impacting reimbursement models and profitability. Geopolitical tensions and trade policies, particularly with China, pose risks to the supply chain for raw materials and drug manufacturing.

Comparison to Industry Standards

• Vafseo is the only oral HIF-based treatment available in the U.S. for anemia due to CKD in dialysis patients, differentiating it from injectable erythropoiesis stimulating agents (ESAs) like Amgen's Epogen and Aranesp, Johnson & Johnson's Procrit, and Roche's Mircera.
• In Japan, Vafseo competes with other HIF-PH inhibitors such as roxadustat, daprodustat, and enarodustat, indicating a competitive landscape for this class of drugs.
• Auryxia competes with established phosphate binders like Sanofi's Renagel/Renvela, Fresenius Medical Care North America's PhosLo/Phoslyra and Velphoro, and Shire's Fosrenol, many of which now have generic forms.
• The entry of Ardelyx's XPHOZAH in October 2023 as an add-on therapy for phosphate reduction introduces new competition for Auryxia, targeting patients with inadequate response to traditional binders.
• The company's reliance on single-source third-party manufacturers for Auryxia and Vafseo drug substance and product (e.g., Patheon in Canada, WuXi STA in China, Siegfried in France, Esteve in Spain) is common in the biopharmaceutical industry but carries inherent supply chain risks compared to companies with diversified or in-house manufacturing capabilities.
• The company's recent shift to net income and positive stockholders' equity, while significant, follows a history of substantial losses, indicating a turnaround but also a need for sustained performance to align with more established profitable biopharmaceutical companies.

Corporate Governance

Legal Proceedings

• Dr. Reddys Laboratories Limited filed an opposition to Indian Patent No. 287720 (covering vadadustat composition of matter) in September 2018; amended claims were published on May 9, 2025.
• Sandoz AG filed an opposition against European Patent No. 3007695 (covering vadadustat once daily dosing regimen) on November 6, 2024; the company submitted a reply on March 18, 2025.
• Ardelyx, Inc. filed a lawsuit against the U.S. Department of Health and Human Services (HHS) and CMS in July 2024, alleging that CMS's plan to include oral-only phosphate lowering therapies in the ESRD PPS violated its authority. A preliminary injunction was denied, and the government's motion to dismiss was granted on November 8, 2024. Ardelyx filed a notice of appeal on December 26, 2024, with oral argument scheduled for September 25, 2025.
• The company is exposed to potential litigation and damages under the CREATES Act by competitors who may claim insufficient quantities of approved products are provided for testing generic/biosimilar applications.

Related Party Transactions

• CSL Vifor (now part of CSL Limited) previously held 7,571,429 shares of common stock, which were issued in connection with the Vifor License Agreement and related investment agreements. The $43.3 million consideration received from CSL Vifor was reclassified as debt following the Vifor Termination Agreement.
• The company has a Working Capital Fund liability with CSL Vifor, where CSL Vifor contributed $40.0 million, to be repaid through quarterly tiered royalty payments on Vafseo U.S. net sales starting July 1, 2025.
• The company sold its right to receive royalties and sales milestones for Vafseo in Japan and certain other Asian countries to HealthCare Royalty Partners IV, L.P. (HCR) for $44.8 million, subject to annual and aggregate caps.

Stakeholder Impact

• **Shareholders**: Experienced dilution from recent public and at-the-market offerings, but also benefited from the company's shift to net income and positive stockholders' equity, potentially increasing stock value. Stock price volatility remains a risk.
• **Employees**: Workforce reductions in 2022 impacted employees. The company faces challenges in attracting and retaining qualified personnel in a competitive industry.
• **Customers (Dialysis Organizations, Wholesale Distributors, Specialty Pharmacies)**: Vafseo's U.S. launch and commercial supply agreements with nearly 100% of dialysis organizations aim to provide broader access to an oral anemia treatment. Changes in reimbursement policies (ESRD bundle) and generic competition for Auryxia could affect product availability and pricing for customers.
• **Suppliers/Contract Manufacturers**: The company's reliance on single-source third-party manufacturers for Auryxia and Vafseo creates dependency and potential risks of supply disruptions or increased costs for suppliers.
• **Creditors (BlackRock, CSL Vifor, HCR)**: The company's debt obligations and royalty payment agreements with these entities are critical to its financial structure. Compliance with covenants and repayment schedules directly impacts these creditors.
• **Patients**: Vafseo's approval provides a new oral treatment option for anemia in dialysis-dependent CKD patients. Ongoing pediatric studies for Auryxia and Vafseo label expansion efforts aim to address unmet needs in broader patient populations. However, potential side effects and regulatory restrictions could impact patient access or safety.

Next Steps

• Initiate VALOR, a Phase 3 cardiovascular outcome study for Vafseo in late-stage CKD anemia patients not on dialysis, by the end of 2025.
• Continue efforts to remediate the identified material weakness in internal control over financial reporting related to inventory accounting.
• Continue to work towards completing the post-approval pediatric study for Auryxia's Hyperphosphatemia Indication.
• Monitor the impact of Auryxia's loss of exclusivity and the entry of generic versions on future revenue.
• Manage the increasing cost of product and other revenue for Vafseo as reduced-cost inventory is utilized.
• Engage in ongoing negotiations and technical meetings regarding the proposed overhaul of the EU general pharmaceutical legislative framework.
• Continue to comply with the BlackRock Credit Agreement covenants, including maintaining minimum cash balance or trailing twelve-month revenue.

Key Dates

Recommendation

Akebia Therapeutics has demonstrated a significant financial turnaround, moving to profitability and strengthening its cash position, largely driven by the successful U.S. launch of Vafseo. The broad commercial coverage for Vafseo in dialysis organizations is a strong positive. However, the company faces inherent risks, including the impact of Auryxia's loss of exclusivity, increased debt-related expenses, and an identified material weakness in internal controls. The ongoing legal and regulatory challenges, coupled with the lengthy and uncertain nature of clinical development for label expansion, introduce considerable uncertainty. While the recent performance is encouraging, the substantial risks and the need for sustained execution warrant a 'Hold' recommendation for a seasoned investor, suggesting observation of continued operational improvements and risk mitigation before a more aggressive stance.

Keywords

Biopharmaceutical, Kidney Disease, Anemia, Vafseo, Vadadustat, Auryxia, Ferric Citrate, Dialysis, CKD, HIF-PH Inhibitor, ESRD, Hyperphosphatemia, Iron Deficiency Anemia, NDA Approval, Commercialization, SEC Filing, 10-Q, Financial Results, Pharmaceuticals, Biotech